LEIDEN, Netherlands & CAMBRIDGE, Mass., March 25, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced that Company management will pres
… has started in study PQ-010-001, a global Phase 1b clinical study of QR-010, a novel investigational RNA … of CF. We are very pleased to participate in the first clinicaltrial for this novel compound," said Professor Stuart Elborn …